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INTRODUCTION
Normal platelet function is essential for preventing
excessive blood loss and the formation of intravascu-
lar thrombi. Historically, platelet function testing has
been mainly directed towards detecting hyporeactivi-
ty in the investigation of bleeding disorders. How-
ever, morbidity and mortality caused by thrombosis
far exceeds that as a result of bleeding diatheses.
Platelets are major contributors to the thrombotic
process in many common disorders such as acute
myocardial infarction (AMI) (Furman et al., 2001a),
stable and unstable angina (Vidal et al., 2001),
peripheral arterial disease (Cassar et al., 2003) and
acute cerebral ischaemia (Zeller, Tschoepe & Kessler,
1999). A blood test that can reflect in vivo platelet
activation is potentially a powerful tool in the clinical
laboratory.
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Platelet activation occurs in a variety of clinical situations in which it
directly contributes to the pathology. This study reports a simple flow
cytometric assay for platelet activation which measures platelet-derived
microparticles, activated platelets and platelet–monocyte complexes.
Pre- and post analytical conditions were investigated and optimized
and a normal range established on 20 healthy controls. Twenty patients
pre- and post percutaneous coronary intervention (PCI) were tested
with the technique. Soluble activation markers sCD40 ligand and sP-
selectin and plasma phospholipid levels were measured in both groups.
There was a significant increase in activated platelets and platelet–
monocyte complexes between normal and pre-PCI (P = 0.005 and
0.0275, respectively) suggesting an activated state. There was a
significant fall in activated platelets post-PCI (P = 0.0027) which was
mirrored by a fall in soluble CD40 ligand, soluble P-selectin and plasma
phospholipid levels (P = 0.0066, <0.0001 and 0.0032, respectively)
consistent with antiplatelet therapy administered during the process.
This is a reliable and rapid method for the assessment of ex vivo platelet
activation which may be an aid in diagnosis and help guide therapy for
patients with thrombotic disease.
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Activation of platelets causes a series of morpholog-
ical and functional changes including a conforma-
tional change in glycoprotein (GP) IIb-IIIa, membrane
rearrangement with microparticle formation, expres-
sion of neoantigens such as P-selectin and the rapid
formation of platelet–leucocyte aggregates (for review
see Hickerson and Bode, 2002). These changes can be
detected by flow cytometry using a wide range of
monoclonal antibodies available as markers of plate-
lets and platelet activation.
Several modifications of flow cytometry for plate-
let analysis have been reported, including the use of
either washed platelets (Wehmeier et al., 1991),
platelet rich plasma (Ejim et al., 1990) or whole
blood (Shattil, Cunningham & Hoxie, 1987). As the
physiological function of platelets is to respond rap-
idly to procoagulant stimuli, they are susceptible to
artefactual activation following venesection. Whole
blood techniques minimize activating platelets by
avoiding centrifugation. Some investigators have
used red cell lysis to provide clearer delineation of
the platelet and white cell populations (Furman
et al., 1998; Barnard et al., 2003; Ray et al., 2005).
However, it has been reported that lysis may also
lead to artefactual activation (Li, Goodall & Hjem-
dahl, 1997).
Until recently, surface P-selectin expression (CD62)
has been considered as the gold standard marker of
platelet activation; however, degranulated platelets
lose their surface P-selectin (Michelson et al., 2001).
Platelets expressing P-selectin also rapidly adhere to
white blood cells via P-selectin glycoprotein ligand-1
(Andre, 2004). The formation of platelet–leucocyte
aggregates, particularly platelet–monocyte complexes,
has been reported to be a reliable marker of activation
(Michelson et al., 2001).
There are two reported approaches for detection of
platelet–monocyte complexes. Barnard et al. (2003)
lysed whole blood to remove red blood cells, whereas
Hagberg and Lyberg (2000) reported a technique with
no lysis, centrifugation or washing of samples with
reduced potential for inducing ex vivo platelet activa-
tion.
In this study, a flow cytometric technique for the
evaluation of platelet activation in whole blood sam-
ples has been optimized. Artefactual platelet activation
has been minimized by avoiding centrifugation, wash-
ing, vortexing and red blood cell lysis. Samples have
been processed rapidly and fixed with paraformalde-
hyde after incubation with antibodies. This technique
has been used to measure platelet-derived microparti-
cles (PDM), activated platelets expressing CD62 and
platelet–monocyte complexes in normal, as well as
clinical samples from patients with acute coronary
syndrome who underwent early PCI.
These cellular markers have been compared with
plasma markers of platelet activation, soluble CD40
ligand and soluble P-selectin. We have also reported a
new method, factor X-activated clotting (XACT). This
technique is sensitive to procoagulant phospholipid
present in patient plasma and is based on the capacity
of a sample to shorten the clotting time of phospho-
lipid depleted plasma (Exner et al., 2003).
MATERIALS AND METHODS
Ethics
Use of clinical samples for this study were approved
by the ethics committee of Royal Perth Hospital (Prac-
tical Study EC 2004/030).
Blood samples
Venous blood was collected by clean venipuncture
into vacuum tubes containing 0.109 M buffered
sodium citrate, 15 mM theophylline, 3.7 mM adeno-
sine and 0.198 mM dipyridamole (CTAD tubes; Becton
Dickinson, Franklin Lakes, NJ, USA) or 0.106 M
sodium citrate (Becton Dickinson). Samples were
gently mixed by inversion.
Controls
Blood was collected from 20 healthy volunteers (10
males, range: 21–53 years and 10 females, range: 21–
43 years), who had not taken aspirin or nonsteroidal
anti-inflammatory drugs within the previous 10 days.
These controls were used to establish normal ranges
for activated platelets, PDM and platelet–monocyte
complexes.
Patients
Patients were male or nonpregnant females aged at
least 18 years of age presenting with unstable angina
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or non-ST-elevation myocardial infarction who under-
went early percutaneous coronary intervention (PCI)
within 48 h of presentation. They were excluded if
they had active bleeding, a high risk of bleeding, had
taken nonsteroidal anti-inflammatory drugs other
than aspirin less than 48 h prior to presentation, and
had been administered glycoprotein IIb/IIIa inhibitors,
thienopyridines or dipyridamole within 7 days prior to
presentation. Patients were given aspirin 300 mg (if
not already on aspirin) and clopidogrel (300 or
600 mg) at least 2 h prior to the procedure. Blood
samples were collected postdose but prior to PCI. Hep-
arin was administered for PCI, and in 17/20 patients
abciximab, a glycoprotein IIb/IIIa inhibitor, was also
administered with a bolus of 0.25 mg/kg followed by
a continuous infusion of 0.25 lg/kg/min post proce-
dure. Further blood samples were collected the next
day.
Platelet-derived microparticles and activated platelets
Fifty microlitres of whole blood was diluted with
950 ll phosphate buffered saline pH 7.4 (23.4 g/l
NaH2PO4.2H2O, 21.3 g/l Na2HPO4, 9.0 g/l NaCl) con-
taining 3.35 g/l of dipotassium EDTA and 2 g/l bovine
albumin (PBS/EDTA/albumin buffer). Fifty microlitres
of this diluted whole blood was incubated at room
temperature for 15 min with 5 ll murine monoclonal
anti-CD61 (GPIIIa) labelled with fluorescein isothio-
cyanate (FITC) (DAKO, Glostrup, Denmark) and 5 ll
murine monoclonal anti-CD62 (P-selectin) labelled
with R-phycoerythrin (RPE) (DAKO) and gently
mixed. Following incubation, samples were fixed by
adding 500 ll of 1% paraformaldehyde (Sigma Chem-
ical Co, St Louis, MO, USA) in PBS (pH 7.4). Ten
microlitres of fluorospheres (Coulter Corp., Miami,
FL, USA) were added as an internal standard to
quantitate platelet-derived microparticles. Samples
were mixed by inversion and analysed using a Coul-
ter EPICS XL-MCL flow cytometer (Coulter Corp). All
antibodies were titrated to determine saturating
concentrations.
Platelets were gated on CD61 positivity and acti-
vated platelets were detected by the presence of sur-
face P-selectin (CD62). Results were expressed as a
percentage of total platelets. Using flow beads of
standard size (Flow Check; Polysciences Inc, Warring-
ton, PA, USA) platelet-derived microparticles were
characterized by size [less than 1 lm (Heijnen et al.,
1999)] and CD61 positivity (Figure 1). Isotype
matched controls (DAKO) were used to correct for
nonspecific binding. Data acquisition was stopped
after 1000 fluorospheres were counted. To quantitate
the concentration of PDM, the following calculation
was used:
(Test Count)Isotype Control Count) · blood dilu-
tion · proportion of flow beads counted to total
amount added. Results were reported as ·108/l.
Detection of platelet–monocyte complexes
Fifty microlitres of whole blood was diluted with
450 ll PBS/EDTA/albumin buffer. Fifty microlitres of
this diluted whole blood was incubated at room tem-
perature with 10 ll murine monoclonal antibodies,
anti-CD61-FITC, anti-CD45 R-phycoerythrin cova-
lently linked to cyanine 5 (PeCy5) (Coulter, Immuno-
tech, Marseille, France) and anti-CD14-RPE (DAKO)
for 15 min. After incubation, 500 ll of 1% parafor-
maldehyde in distilled water was added as a fixative.
Samples were gently mixed by inversion and analysed
by flow cytometry.
Leucocytes were selected from red blood cells using
the specific marker CD45 PeCy5. A scatter plot of for-
ward vs. side scatter was used to identify the three dis-
tinct subpopulations of leucocytes. A gate was drawn
around the monocyte population for further analysis.
Cells positive for both anti-CD14 expression and CD61
expression were identified as platelet–monocyte com-
plexes. (Figure 2). Cells were counted for 5 min. Iso-
type-matched negative controls were performed to
check for nonspecific binding. Results were expressed
as a percentage of the total monocyte positive
population.
Stability studies
Blood samples were processed for PDM, activated
platelets and platelet–monocyte complexes immedi-
ately after collection and at 30 min, 1 h, 2 h and 6 h
post venipuncture, in both CTAD and citrated tubes. In
a separate experiment, blood samples fixed with 1%
paraformaldehyde postincubation were read on the
EPICS XL-MCL flow cytometer at 1-h intervals for 5 h.
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Detection of activation by in vitro stimulation
Citrated whole blood was stimulated in vitro with a
final concentration of 1 lg/ml of collagen (Helena
Laboratories, Mt Waverley, Australia) at 37 C for
15 min. Samples were processed pre- and post activa-
tion for PDM, activated platelets and platelet–mono-
cyte complexes.
Plasma markers of platelet activation
Citrated blood samples were spun at 1300 g for
10 min and plasma aliquots were snap frozen in liquid
nitrogen and stored at )80 C until assayed. Commer-
cial sandwich ELISA kits (Bender MedSystems, San
Bruno, CA, USA) were used to quantify plasma plate-
let activation markers, soluble CD40 ligand and soluble
P-selectin.
Plasma procoagulant phospholipid
Citrated blood samples were spun at 1300 g for 10 min
and plasma aliquots were snap frozen in liquid nitrogen
and stored at )80 C until assayed. Centrifuged plasmas
had residual platelet counts of <3 · 109/l. A commer-
cial kit (XACT, Haematex Research, Hornsby, Austra-
Histogram 1 




Figure 1. Flow cytometric analysis of platelet-derived microparticles (PDM) and activated platelets. Platelets are
discriminated from leucocytes and erythrocytes based on typical forward scatter (FS) and side scatter (SS) proper-
ties in histogram 1. PDM are characterized by their size and positivity for CD61-FITC and FS in histogram 2.
Platelets with surface P-selectin expression (CD62) can be seen in histogram 3.
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lia) was used to quantify procoagulant phospholipid.
This is a clotting technique with phospholipid free por-
cine plasma and activated factor X. The phospholipid in
the patient plasma shortens the clotting time and is the
rate limiting factor. The assay was performed on the
STAR automated coagulation analyser (Diagnostica
Stago, Asnie`res, France).
Statistical methods
Data are presented as median and range. Data nor-
mally distributed were compared by a Student’s
t-test. Mann–Whitney U-test (unrelated groups) and
the Wilcoxon signed ranks test (two related samples)
were used to assess non-normally distributed data.




Figure 2. Flow cytometric analysis of platelet–monocyte aggregates in whole blood. The instrument is triggered by
the fluorescence signal and CD45-PeCy5 positive events (leucocytes) and are gated by A in histogram 1. These
are then discriminated by their forward scatter (FS) and side scatter (SS) characteristics in histogram 2, mono-
cytes are discriminated by rectangle B. Events presenting in B are considered monocytes and are subjected to
two-colour analysis (CD61-FITC and CD14-RPE) in histogram 3 for the discrimination of platelet–monocyte
complexes.
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Platelet-derived microparticles levels were stable for
2 h in both citrate and CTAD tubes but increased by
1.8% in citrate tubes and 1.49% in CTAD tubes after
6 h (mean of five experiments). Activated platelets
increased from 0.45% immediately after collection to
1.06% after 2 h and 3.59% after 6 h in citrate tubes
and at the same time-point levels were 0.29, 0.31 and
3.84%, respectively, in CTAD tubes (mean of five
experiments). Platelet–monocyte complexes rose from
a baseline 3.05 to 5.06% at 2 h and 11.5% at 6 h in
citrate anticoagulant and were 3.11, 4.15 and 10.4%,
respectively, in CTAD (mean of five experiments). For
the remainder of the study, sodium citrate tubes were
processed within 30 min or CTAD tubes within 2 h
post venepuncture.
The effect of fixing whole blood with 1% parafor-
maldehyde was examined over a 6-h period. All sam-
ples were stable for 2 h post fixation in the fridge
(data not shown).
Detection of activation poststimulation
In an unstimulated sample PDM, activated platelets
and platelet–monocyte complexes were 184 · 108/l,
0.87 and 2.71%, respectively. Upon stimulation with
a final concentration of 1 lg/ml of collagen at 37 C
for 15 min, all markers of platelet activation
increased; PDM 434 · 108/l, activated platelets 40.1%
and platelet–monocyte complexes 17.1%. With final
collagen concentrations of 5 and 10 lg/ml, the results
were PDM 492 and 726 · 108/l, activated platelets
59.6 and 89.4% and platelet–monocyte complexes
71.3 and 86.1%, respectively.
Reproduceability
The intra-assay coefficient of variation for the same
sample 5 consecutive times was 5.3% for PDM,
10.9% for activated platelets and 13.3% for platelet–
monocyte complexes.
Normal values
Twenty healthy volunteers were assessed for all mark-
ers of platelet activation. The results for PDM ranged
from 38 to 216 · 108/l, activated platelets 0.1–1.03%
and platelet–monocyte complexes 0.64–7.48%. The
results for this group are summarized in Table 1. The
results of the plasma markers soluble P-selectin, solu-
ble CD40 ligand and procoagulant phospholipid XACT
test are shown in Table 2.
Patients
Activated platelets and platelet–monocyte complexes
were higher in the pre-PCI samples compared with
the normal values. After the procedure, circulating












106 (42–216) 83 (38–212) 90 (28–265) NS NS NS
Activated platelets (%) 0.39 (0.11–1.03) 0.95 (0.05–3.48) 0.57 (0.25–1.77) 0.005 NS 0.0027
Platelet monocyte
complexes (%)
2.98 (0.64–7.48) 4.33 (1.73–10.60) 3.91 (2.07–13.4) 0.0275 0.0349 NS
There was a significant increase in activated platelets and platelet monocyte complexes between pre-PCI patients and
normal samples. The data presented are median (range). NS, not significant.
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activated platelets were no longer significantly differ-
ent to normal. Platelet–monocyte complexes were still
increased although less significantly so. Pre-PCI PDM
values were not significantly different to normal and
were unchanged post-PCI. (Table 1).
There was no significant difference in soluble plate-
let activation markers between normal and patient
pre-PCI. Post-PCI levels of plasma phospholipid and
sCD40 ligand were significantly lower than normal
values and all three plasma markers were significantly
lower post-PCI vs. pre-PCI. (Table 2).
DISCUSSION
Circulating activated platelets have been associated
with many common disorders including stable and
unstable angina (Vidal et al., 2001), acute myocardial
infarction (Furman et al., 2001a), diabetes mellitus
(Nomura et al., 1995), angioplasty (Michelson et al.,
2001), cardiopulmonary bypass (Nannizzi-Alaimo
et al., 2002), acute cerebral ischaemia (Zeller,
Tschoepe & Kessler, 1999), myeloproliferative disor-
ders (Wehmeier et al., 1991) and peripheral arterial
disease (Cassar et al., 2003).
Flow cytometry is a versatile tool that can be uti-
lized to quantitatively assess the physical and anti-
genic properties of platelets (Linden et al., 2004). A
major challenge in analysing the activation status of
circulating platelets is to avoid artefactual in vitro acti-
vation. The technique reported here minimizes arte-
factual trauma by testing in whole blood, avoiding red
blood cell lysis, centrifugation and washing steps. The
samples are fixed with 1% paraformaldehyde postan-
tibody labelling to increase the sample stability. The
method is rapid, easy to perform and simultaneously
measures a panel of platelet activation markers.
Sodium citrate is the most commonly used anti-
coagulant for platelet activation studies (Schmitz et al.,
1998). This work shows that citrate samples need to
be processed within 30 min of venepuncture. CTAD
anticoagulant contains platelet inhibitors to minimize
ex vivo activation (Mody et al., 1999; Kim et al., 2002).
We found samples collected into these tubes were sta-
ble for 2 h postvenesection.
The intrabatch coefficient of variation (CV) was
below 15% for all markers. The technique was sensitive
to small incremental increases over time and easily
detected the activation changes induced by collagen
stimulation.
Platelet–monocyte aggregates have been reported
to be a more sensitive marker of in vivo platelet acti-
vation than surface P-selectin expression (Michelson
et al., 2001). There are two approaches to identify
platelet–monocyte complexes. First is to use cell sepa-
ration and red blood cell lysis to remove erythrocytes
and allow clear differentiation of white cell popula-
tions. (Li, Goodall & Hjemdahl, 1997; Michelson
et al., 2001; Barnard et al., 2003). An alternative tech-
nique is to avoid lysis thus minimizing platelet acti-
vation (Hagberg & Lyberg, 2000). In the presence of
intact red cells, leucocytes can be discriminated from
erythrocytes by binding of the leucocyte specific anti-
CD45. A combination of a platelet-specific antibody
anti-CD61 and a monocyte-specific antibody, anti-
CD14 allows the detection of platelet–monocyte
complexes (Barnard et al., 2003).












1.87 (0.7–3.55) 1.3 (0.58–2.43) 0.68 (0.14–2.56) NS <0.0001 0.0032
sP-selectin (ng/ml) 30.7 (22.3–69.7) 34.14 (27.95–95.72) 28.77 (19.71–51.14) NS NS 0.0066
SCD40 ligand (ng/ml) 0.46 (0.17–3.82) 0.30 (0.21–1.69) 0.24 (0.03–1.61) NS 0.0006 <0.0001
There was a significant fall in all markers post-PCI. Data presented are median (range).
XACT, activated Factor X assay for procoagulant phospholipid; sP-selectin, soluble P-selectin; sCD40L, soluble CD40
Ligand; NS, not significant.
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Normal reference ranges were determined from 20
healthy volunteers. The reference range for platelet–
monocyte complexes was lower than reported by
some other authors. Ray et al. (2005) reported a refer-
ence range of 3.2–12.4% compared with the reference
range in this study of 0.64–7.48%. The lower refer-
ence range of this study may be due to the avoidance
of red cell lysis. The reference range for activated
platelets (P-selectin expression) in this study correlates
with several other studies (Furman et al., 1998; McCa-
be et al., 2004; Ray et al., 2005). The absolute values
for PDM obtained in this study are higher than those
found in plasma (Kim et al., 2002) most likely because
of the lack of a centrifugation step.
Platelets have a key role in the pathogenesis of
arterial thrombosis and acute coronary syndromes
(Vidal et al., 2001). This study demonstrates a signifi-
cant degree of platelet activation in patients prior to
PCI when compared with the normal population dem-
onstrated by increased platelet expression of surface
P-selectin and platelet–monocyte complexes and cor-
relates well with several other studies (Furman et al.,
2001a; Vidal et al., 2001; Craft et al., 2004; Morel et al.,
2004; Ray et al., 2005). Soluble markers of platelet
activation, CD40 ligand and P-selectin, were not sig-
nificantly different from the normal population in
pre-PCI patients, suggesting flow cytometric analysis
may offer a more sensitive measure of in vivo platelet
activation.
Postpercutaneous coronary intervention is an inva-
sive procedure that results in endothelial trauma and
can contribute to restenosis (Craft et al., 2004; Ray
et al., 2005). Thus, there is an increased need for
adjunctive therapy. Following PCI, there were signifi-
cant decreases in activated platelets, soluble P-selectin,
procoagulant phospholipid and soluble CD40L. This
can be attributed to antiplatelet and anticoagulant
therapy administered prior to, and during, the proce-
dure. Several studies have reported that the use of
GPIIbIIIa inhibitors, oral anticoagulants and aspirin to
decrease platelet activation after PCI (Mascelli et al.,
1998; Furman et al., 2001b; Berg et al., 2002a,b; Ray
et al., 2005).
Platelet–monocyte complexes, however, remained
elevated after PCI and antiplatelet therapy. This is
likely to be due to the dynamic interaction of heparin
anticoagulation and antiplatelet therapy. Michelson
et al. (2001) reported platelet–monocyte complexes
increased immediately post-PCI but returned to base-
line 24 h post-PCI, whereas Furman et al. (2001b)
noted that unfractionated heparin increased platelet–
monocyte complexes. In contrast, two studies have
reported that the use of GPIIbIIIa inhibitors lowers
platelet–monocyte complexes (Furman et al., 2001b;
Ray et al., 2005).
Several groups have shown an increase in sCD40L
in patients requiring PCI (Aukrust et al., 1999; Srini-
vasa Prasad et al., 2003) as well as post-PCI (Quinn
et al., 2004). However, this study found significantly
decreased levels in both groups when compared with
normal samples. Quinn et al. (2004) reported clopido-
grel treatment prior to PCI had no effect on elevated
serum CD40L levels post-PCI. The difference in these
results may be due to sample type. Thom et al. (2004)
reported that sCD40L is significantly higher in serum
when compared with citrated plasma and the degree
of elevation in serum is proportional to the time
elapsed after venepuncture until the sample has fully
clotted. Citrated plasma is more likely to represent
in vivo physiological levels of soluble CD40L.
During platelet activation, anionic phospholipids
are exposed to the platelet surface and PDM are
formed creating a procoagulant surface. This is the
matrix for the reaction of factor Xa, thrombin and
fibrin clot formation (Holme, Brosstad & Solum,
1995). The XACT test is a new method that quanti-
tates procoagulant phospholipid in plasma (Exner
et al., 2003). Test plasma is mixed with phospholipid
free porcine plasma and activated factor X. Anionic
phospholipid in the patient plasma is rate limiting and
will shorten clotting in proportion to its concentra-
tion. The method is easily automated and the clotting
time in seconds is converted to a concentration of
phospholipid by extrapolation from a standard curve.
This technique demonstrated a significant decrease in
procoagulant phospholipid post-PCI which mirrored
the decrease in activation observed in other markers
of platelet activation such as sP-selectin, sCD40 ligand
and activated platelets. This may be a useful rapid
method to measure platelet activation in plasma.
Interestingly, there was not a corresponding decrease
in PDM suggesting the relationship between PDM and
plasma phospholipid in whole blood may be more
complex than simply numerical.
This paper reports a whole blood flow cytometric
technique for the detection of PDM, activated platelets
 2008 The Authors
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and platelet–monocyte complexes, which offers the
advantage of minimal sample manipulation avoiding
artefactual platelet activation. Using the technique,
we have developed normal ranges for PDM, activated
platelets and platelet monocyte complexes. We exam-
ined a group of patients pre- and post-PCI and found
evidence of activation prior to procedure and a
marked decrease in platelet activation post-PCI, sug-
gesting effectiveness of clinical intervention. A limita-
tion of this study is the small number of patients
analysed. Larger prospective studies are required to
confirm the decrease in platelet activation markers
post-PCI with adjunctive therapy.
The morbidity and mortality caused by thrombosis
far exceeds that as a result of bleeding diatheses. A
platelet activation profile that includes the enumera-
tion of PDM, activated platelets and platelet-monocyte
complexes may be useful to predict the risk of throm-
bosis, monitor antiplatelet therapy and assess the
effectiveness of clinical intervention.
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